Author Archives: Zeteo Biomedical LLC

Zeteo Biomedical Expands into Pulmonary Drug Delivery with AriesMR Active Dry Powder Inhaler

New ZTECH-P™ pulmonary platform provides active, propellant-free powder aerosolization without reliance on patient inspiratory effort and supports single- and dual-API combination products

AUSTIN, Texas, Sept. 15, 2026 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC today announced the expansion of its ZTECH-P™ powder drug-delivery platform into pulmonary delivery with the introduction of AriesMR™, a reloadable active dry powder inhaler designed for controlled pulmonary administration of pharmaceutical powders without reliance on patient-generated inspiratory energy for powder aerosolization or the use of CFC/HFA propellants.

Image caption: AriesMR™ Active Dry Powder Inhaler.

Unlike conventional passive dry powder inhalers that depend substantially on a patient’s inspiratory effort to disperse and aerosolize a formulation, AriesMR uses an integrated mechanical energy source to actively aerosolize and deliver the powder. The orientation-independent platform provides configurable dose and aerosolization parameters that can be optimized with formulation and particle characteristics for pulmonary delivery.

“AriesMR extends technologies we have developed and refined for nasal powder delivery into a pulmonary platform designed around many of the same challenges our pharmaceutical partners face—dose control, formulation protection, combination-product development and scalable manufacturing,” said Timothy Sullivan, Founder and Chief Executive Officer of Zeteo Biomedical.

“Importantly, the technology provides active powder aerosolization without requiring either HFA propellants or the patient’s inspiratory effort as the primary energy source for powder dispersion.”

The platform provides pharmaceutical developers with another approach to pulmonary combination-product development at a time when the industry is evaluating new inhalation technologies, including propellant-free alternatives to conventional pressurized inhaler platforms.

AriesMR incorporates replaceable unit-dose powder cartridges in a compact, mechanically actuated device, with on-board storage for up to six cartridges and a removable and replaceable mouthpiece. The device requires no battery power and is designed to operate independently of device orientation.

The platform can support single-API and dual-API configurations, including architectures in which separate powder formulations are maintained within the primary packaging until the point of delivery. This capability may enable combination-product strategies where formulation compatibility, stability or other development considerations make conventional co-formulation difficult.

AriesMR is being developed as part of Zeteo’s integrated combination-product development platform, bringing together delivery-device engineering, formulation and particle optimization, unit-dose primary packaging, product characterization and manufacturing technology. The platform is designed to support programs from early feasibility and preclinical development through clinical translation and commercial scale-up.

The expansion into pulmonary delivery builds on Zeteo’s existing ZTECH-P™ and ZTECH-L™ platforms supporting nasal, nose-to-brain, ophthalmic, sublingual and other non-invasive routes of administration.

Sullivan will participate in the IPAC-RS 2026 Nasal Innovation Forum, September 16–17 in Jersey City, New Jersey, where Zeteo will present work involving its intranasal powder delivery technology and meet with pharmaceutical and drug-delivery developers.

“Many of the formulation, device, primary-container and manufacturing challenges encountered in nasal powder development have direct parallels in pulmonary combination-product development,” Sullivan added. “The Forum provides an opportunity to discuss how those capabilities can be applied across both routes and to explore pulmonary programs where an active, propellant-free powder delivery approach may offer advantages.”

Learn more: https://zeteobiomed.com/pulmonary-drug-delivery/

ABOUT ZETEO BIOMEDICAL

Zeteo Biomedical LLC is a Cedar Park, Texas-based drug delivery technology and combination-product development company. Zeteo develops configurable delivery platforms for powder and liquid formulations across nasal, pulmonary, ophthalmic, sublingual and other non-invasive routes of administration. The company’s capabilities integrate delivery-device engineering, primary packaging, formulation and product development, in vitro characterization, manufacturing technology and commercialization support. For more information, visit Zeteo Biomedical to learn more about the AriesMR™ active dry powder inhaler: https://zeteobiomed.com/

Media Contact: Cathy Diehl, zeteo@zeteobiomed.com

MULTIMEDIA

Image link for media: https://www.Send2Press.com/300dpi/26-0915-s2p-ariesmr-300dpi.webp

Image caption: AriesMR™ Active Dry Powder Inhaler

LOGO: https://zeteobiomed.com/wp-content/uploads/2026/09/ZeteoLogo-transparent.png

NEWS SOURCE: Zeteo Biomedical LLC

This press release was issued on behalf of the news source (Zeteo Biomedical LLC), who is solely responsible for its accuracy, by Send2Press Newswire. Image, if any, was provided by the news source and not this website or the wire service. Information is believed accurate, as provided by the news source, but is not guaranteed.

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-expands-into-pulmonary-drug-delivery-with-ariesmr-active-dry-powder-inhaler/

Zeteo Biomedical Secures Global Patents for Nasal and Ophthalmic Drug Delivery Device Innovations

CEDAR PARK, Texas, June 11, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical, a privately held biomedical device company, today announced the issuance of new patents in the United States and European Union for its advanced drug delivery technologies. The patents, titled “Cartridge Devices for Administration of a Medicament” (U.S. Patent No. 12329949) and “Hand-Operated Devices for Administration of a Medicament” (EU Patent No. 3946526), further strengthen Zeteo’s ZTech™ delivery platform portfolio for the administration of drugs and biologics via nasal, ophthalmic, and sublingual routes.

Image caption: Zeteo Biomedical.

These patented innovations advance Zeteo’s ZTech-L™ and ZTech-P™ delivery systems, which include both single-use disposable and multi-dose, cartridge-reloadable handheld devices. The platforms support the administration of therapeutics in both liquid and dry powder formulations, including vaccines, biologics, and specialty drugs. Nasal delivery, in particular, is emerging as a highly effective, non-invasive alternative for treating conditions such as pain, emesis, seizures, neurodegenerative and autoimmune disorders, infectious diseases, and bioterror threats.

“We are seeing increasing global demand for metered-dose nasal, ophthalmic, and sublingual delivery devices that are compact, intuitive, and suitable for self-administration,” said Timothy Sullivan, CEO of Zeteo Biomedical. “A unique feature that sets our device technology apart is its ability to function reliably in any physical orientation, making it ideal for medication delivery in both terrestrial and space-based microgravity environments. This capability opens exciting new frontiers for Zeteo including applications in space-based healthcare.”

Zeteo’s integrated delivery platforms and technical services streamline the development and commercial-scale production of patient-centric drug/device combination products for pharmaceutical and biotech partners. This focus on patient-friendly design improves treatment adherence and medical outcomes, while enhancing product differentiation and brand value for manufacturers.

Zeteo’s platform technologies are designed to meet the evolving demands of global and interstellar healthcare markets, delivering precision, performance, and portability for the next-generation of therapeutic drug/device combination products.

About Zeteo Biomedical LLC

Zeteo Biomedical is a Texas-based medical device company focused on the development and commercialization of advanced drug and biologic delivery systems. The company specializes in intranasal, ophthalmic, and sublingual delivery technologies designed to improve patient outcomes through precision dosing, portability, and ease of use. Zeteo’s proprietary platforms are supported by an extensive patent portfolio and a range of product development services tailored to accelerate time to market for pharmaceutical and biotech clients worldwide.

To learn more, visit https://zeteobiomed.com/.

MEDIA CONTACT:
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

NEWS SOURCE: Zeteo Biomedical LLC

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-secures-global-patents-for-nasal-and-ophthalmic-drug-delivery-device-innovations/

Zeteo Biomedical Introduces CygnusMR™ and CygnusSDX™ Delivery Devices for Nasal Administration of Dry Powder Drugs and Biologics

Innovative Needle-Free Nasal Powder Delivery Systems Enhance Drug and Vaccine Development

CEDAR PARK, Texas, Feb. 19, 2025 (SEND2PRESS NEWSWIRE) — Zeteo Biomedical LLC today announced the launch of its ZTech-P CygnusMR™ and CygnusSDX™ delivery devices, designed for precise, metered-unit dosing of dry powder drugs and biologics via systemic nasal and nose-to-brain administration. These innovative needle-free delivery systems provide pharmaceutical and biotech companies with advanced solutions to accelerate the development, clinical evaluation, and commercial deployment of dry powder nasal combination products for a broad range of therapeutic applications.

Image Caption: Zeteo Biomedical Introduces CygnusMR™ and CygnusSDX™ Delivery Devices for Nasal Administration of Dry Powder Drugs and Biologics.

Intranasal dry powder formulations offer significant advantages, including enhanced stability, extended shelf life, and improved bioavailability. Systemic nasal administration enables rapid, needle-free drug uptake, while nose-to-brain delivery bypasses the blood-brain barrier, allowing direct therapeutic access to the brain. The CygnusMR and CygnusSDX devices are designed for both patient self-administration and caregiver-assisted use, with configurations available for both adult and pediatric patients as well as a variety of animal species.

“The CygnusMR nasal delivery device is the industry’s first cartridge-reloadable nasal powder delivery system, featuring onboard storage for up to six unit doses and a replaceable nasal tip,” said Timothy Sullivan, CEO of Zeteo Biomedical. “Both the CygnusMR and CygnusSDX devices have undergone extensive analytical and in-vivo preclinical testing over the past several years to ensure optimal performance and reliability.”

Zeteo’s intranasal delivery devices leverage proprietary packaging technology that utilizes a Form Fill Seal (FFS) flexible foil blister system, eliminating the supply chain constraints associated with traditional drug packaging methods such as syringes and glass vials. This innovative approach provides superior protection for pharmaceuticals and biologics while allowing for storage under room temperature, refrigerated, or frozen conditions. The scalable ZTech FFS packaging platform enables the high-volume production of millions of doses per day—a critical capability for the rapid, cost-effective deployment of vaccines and medical countermeasures on a global scale.

Learn more: https://zeteobiomed.com/intranasal-drug-delivery/

About Zeteo Biomedical LLC:

Zeteo Biomedical™ is a leading biomedical device technology company headquartered in Cedar Park, Texas. The company provides novel technology and technical services supporting the development and commercialization of drug/device combination products, and fill/finish packaging solutions for pharmaceuticals, biopharmaceuticals, biologics, and botanicals. Zeteo’s technology applications include drug/device combination products for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

IMAGE link for media: https://www.Send2Press.com/300dpi/25-0219-s2p-zeteo-nasal-300dpi.jpg

Image Caption: Zeteo Biomedical Introduces CygnusMR™ and CygnusSDX™ Delivery Devices for Nasal Administration of Dry Powder Drugs and Biologics.

NEWS SOURCE: Zeteo Biomedical LLC

To view the original story, visit: https://www.send2press.com/wire/zeteo-biomedical-introduces-cygnusmr-and-cygnussdx-delivery-devices-for-nasal-administration-of-dry-powder-drugs-and-biologics/

Zeteo Biomedical Introduces OrionMRQ™ Nasal Delivery Device for Vaccines

PFLUGERVILLE, Texas /ScoopCloud/ -- Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Nasal administration provides needle free, rapid systemic uptake into the body via the nose. Nasal delivery of vaccines can invoke a fast local immune response in the respiratory track, which is frequently the primary route of infection for contagious pathogens such as pandemic flu or coronavirus. The ZEOx1 OrionMRQ™ device is intuitive to use, enabling either patient self-administration or administration by caregivers with configurations available for both adults and children.

The OrionMRQ reloadable nasal delivery device has the capability to store up to four unit doses in the on-board storage compartment. The device is compact making it easy to carry in a pocket or purse. Zeteo intranasal delivery devices incorporate novel packaging technology utilizing a Form Fill Seal (FFS) flexible foil, packaging the drug or vaccine in a unit dose blister reducing the cost and eliminating the supply chain constraints of glass vials.

ZEOx1™ blister packaging provides exceptional barrier properties to protect the drug or vaccine during storage and transport and can be stored at room temperature, refrigerated or frozen storage conditions. The ZEOx1™ packaging technology is commercially scalable to produce millions of doses per day; a critically important requirement for rapid, cost effective deployment of vaccines and medical countermeasures to global populations.

About Zeteo Biomedical LLC:

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology, drug/device combination product development services and fill/finish packaging technology for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Zeteo Biomedical LLC announced today the availability of the ZEOx1 OrionMRQ™ nasal drug and vaccine delivery device. Zeteo's latest innovative delivery device provides pharmaceutical and biotech companies developing drugs, peptides, proteins, monoclonal antibodies and vaccines with precise, metered unit dose systemic delivery via the nasal route.

Related link: https://www.zeteobiomed.com/

Zeteo Biomedical Receives US Patent for Innovative Sublingual Delivery Device for Vaccines and Pharmaceuticals

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEOx1™ Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Sublingual delivery has emerged as a viable route of administration for vaccines and medications for pain, cardiovascular, allergy, seizure, sedation and emesis. The sublingual route avoids first pass metabolism and provides rapid systemic uptake into the body providing advantages over traditional oral medications.

Zeteo's latest innovations expand its ZEOx1 Hydra™ sublingual delivery device family that include configurations for mono-dose disposable and mono-dose reloadable dispensers for vaccines, drugs, biopharmaceuticals, biologics and botanical liquid formulations. "We see expanding demand for metered dose sublingual delivery devices that are easy to use, convenient to carry, deliver a precise dose and can be self-administered," said Timothy Sullivan, President of Zeteo Biomedical.

Zeteo's delivery device technology and product integration services enable pharmaceutical and biotech manufacturers to develop drug/device combination products that can extend or establish market exclusivity and competitive differentiation for new or existing drugs and biologics. The shift to developing value added, patient-centric products benefit the consumer through improved compliance and health outcomes while building brand value for the pharmaceutical or biotech manufacturer. Zeteo's delivery platforms and products are designed to meet the diverse demands of consumers and pharma manufacturers in globally competitive markets.

About Zeteo Biomedical LLC

Zeteo Biomedical™ is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications.

For more information, please visit the Zeteo website at: https://www.zeteobiomed.com/

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical, a privately held, biomedical device company, announced today it has been awarded a United States Patent for its "Oral Delivery Device and Methods" (US Patent 10238577). This latest patent expands the capabilities of Zeteo's ZEO Delivery Platform to systemically deliver drugs or biologics, into the body non-invasively via the sublingual route.

Related link: https://www.zeteobiomed.com/

Zeteo Biomedical to Collaborate with Iowa State University Nanovaccine Institute to Study a COVID 19 Vaccine Under Fast Track CARES Act Funded Program

AUSTIN, Texas /ScoopCloud/ -- Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2(TM) Delivery Platform, along with technical services to support the evaluation of a room temperature stable SARS-CoV-2 vaccine under development by ISU's Nanovaccine Institute.

Zeteo ZEO(TM) Delivery Platforms provide nasal delivery device configurations to support vaccine development during early stage pre-clinical animal studies, human clinical trials and are commercially scalable to fill/finish and deliver millions of doses per day for a global supply of nasal vaccines or medical countermeasures in the event of a pandemic crisis.

ISU's vaccine is expected to provide long-term protection against SARS-CoV-2, the novel coronavirus that causes COVID-19, and is intended to address some of the limitations of the vaccines currently in development by targeting room temperature storage and single dose nasal self-administration as key capabilities.

"Our approach leverages the strengths of ISU's nanovaccine platform and Zeteo's ZEOx2 nasal delivery platform and brings together a world-class team of scientists and engineers providing expertise for vaccine formulation, pre-clinical and clinical evaluations, fill/fit/finish packaging, nasal delivery devices and manufacturing scale-up," said Dr. Balaji Narasimhan, Director of the Nanovaccine Institute at Iowa State University.

Zeteo's ZEOx2 Delivery Platform includes nasal delivery devices to support powder and reconstituted powder to liquid vaccine formulations that can be either caregiver- or self-administered.

Timothy Sullivan, President of Zeteo Biomedical, said "We are honored to have been selected by the ISU Nanovaccine Institute to provide our technology and expertise in nasal drug delivery and packaging to support this critically important project to address the global health devastation caused by COVID 19."

Additional collaboration partners involved in the project include the Southwest Research Institute (San Antonio, TX), Skroot Laboratory, Inc. (Ames, IA), and the University of Iowa (Iowa City, IA). This is a fast track project and is expected to be completed by the end of the year.

About Zeteo Biomedical LLC

Zeteo Biomedical(TM) is a biomedical device technology company based in Austin, Texas. Zeteo provides patient-centric delivery device technology and unit dose fill/finish packaging for pharmaceuticals, biopharmaceuticals, biologics and botanicals for intranasal, nose-to-brain, ophthalmic, sublingual, and animal care product applications. For more information please visit the Zeteo website at: https://www.zeteobiomed.com/.

Media Contact
Cathy Diehl
Zeteo Biomedical LLC
+(1) 512-614-0144
zeteo@zeteobiomed.com

*LOGO link for media: https://www.send2press.com/300dpi/20-1117s2p-zeteo-biomedical-300dpi.jpg

Zeteo Biomedical LLC, Inc., a privately held medical device company, has partnered with the Nanovaccine Institute at Iowa State University to study a nasal SARS-CoV-2 vaccine. Zeteo will provide nasal delivery device technology and unit dose packaging utilizing its ZEOx2 Delivery Platform.

Related link: https://www.zeteobiomed.com/